NeoGenomics Statistics
Total Valuation
NeoGenomics has a market cap or net worth of $1.81 billion. The enterprise value is $2.00 billion.
| Market Cap | 1.81B |
| Enterprise Value | 2.00B |
Important Dates
The next confirmed earnings date is Tuesday, April 30, 2024, before market open.
| Earnings Date | Apr 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoGenomics has 127.67 million shares outstanding. The number of shares has increased by 1.03% in one year.
| Shares Outstanding | 127.67M |
| Shares Change (YoY) | +1.03% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 1.18% |
| Owned by Institutions (%) | 101.03% |
| Float | 125.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 222.22 |
| PS Ratio | 3.06 |
| Forward PS | 2.73 |
| PB Ratio | 1.92 |
| P/FCF Ratio | n/a |
| PEG Ratio | 3.02 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.20, with a Debt / Equity ratio of 0.65.
| Current Ratio | 6.20 |
| Quick Ratio | 5.67 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.06 |
Financial Efficiency
Return on equity (ROE) is -9.20% and return on invested capital (ROIC) is -6.94%.
| Return on Equity (ROE) | -9.20% |
| Return on Assets (ROA) | -5.20% |
| Return on Capital (ROIC) | -6.94% |
| Revenue Per Employee | $281,735 |
| Profits Per Employee | -$41,890 |
| Employee Count | 2,100 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 14.33 |
Taxes
| Income Tax | -9.13M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.88% in the last 52 weeks. The beta is 1.10, so NeoGenomics's price volatility has been similar to the market average.
| Beta (1Y) | 1.10 |
| 52-Week Price Change | -8.88% |
| 50-Day Moving Average | 15.07 |
| 200-Day Moving Average | 15.46 |
| Relative Strength Index (RSI) | 45.43 |
| Average Volume (30 Days) | 908,262 |
Short Selling Information
The latest short interest is 7.24 million, so 5.67% of the outstanding shares have been sold short.
| Short Interest | 7.24M |
| Short Previous Month | 7.29M |
| Short % of Shares Out | 5.67% |
| Short % of Float | 5.75% |
| Short Ratio (days to cover) | 9.07 |
Income Statement
In the last 12 months, NeoGenomics had revenue of $591.64 million and -$87.97 million in losses. Loss per share was -$0.70.
| Revenue | 591.64M |
| Gross Profit | 244.60M |
| Operating Income | -107.74M |
| Pretax Income | -97.10M |
| Net Income | -87.97M |
| EBITDA | -8.37M |
| EBIT | -90.19M |
| Loss Per Share | -$0.70 |
Balance Sheet
The company has $415.20 million in cash and $611.68 million in debt, giving a net cash position of -$196.48 million or -$1.54 per share.
| Cash & Cash Equivalents | 415.20M |
| Total Debt | 611.68M |
| Net Cash | -196.48M |
| Net Cash Per Share | -$1.54 |
| Equity / Book Value | 941.54M |
| Book Value Per Share | 7.38 |
| Working Capital | 500.51M |
Cash Flow
In the last 12 months, operating cash flow was -$1.95 million and capital expenditures -$28.75 million, giving a free cash flow of -$30.71 million.
| Operating Cash Flow | -1.95M |
| Capital Expenditures | -28.75M |
| Free Cash Flow | -30.71M |
| FCF Per Share | -$0.25 |
Margins
Gross margin is 41.34%, with operating and profit margins of -18.21% and -14.87%.
| Gross Margin | 41.34% |
| Operating Margin | -18.21% |
| Pretax Margin | -16.41% |
| Profit Margin | -14.87% |
| EBITDA Margin | -1.42% |
| EBIT Margin | -15.24% |
| FCF Margin | -5.19% |
Dividends & Yields
NeoGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.03% |
| Shareholder Yield | -1.03% |
| Earnings Yield | -4.87% |
| FCF Yield | -1.70% |
Analyst Forecast
The average price target for NeoGenomics is $19.50, which is 37.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.50 |
| Price Target Difference | 37.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 16, 2003. It was a reverse split with a ratio of 1:100.
| Last Split Date | Apr 16, 2003 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
NeoGenomics has an Altman Z-Score of 1.79 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.79 |
| Piotroski F-Score | 3 |